| 前收市價 | 14.40 |
| 開市 | 14.35 |
| 買盤 | 14.03 x 1800 |
| 賣出價 | 14.13 x 1900 |
| 今日波幅 | 13.85 - 14.78 |
| 52 週波幅 | 3.53 - 23.86 |
| 成交量 | |
| 平均成交量 | 14,913,920 |
| 市值 | 2.07B |
| Beta 值 (5 年，每月) | 1.95 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.05 |
| 業績公佈日 | 2024年8月06日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 22.80 |
Motley FoolIs It Too Late to Buy Novavax Stock?
Shares of the vaccine maker are trading up 230% this year.
Investor's Business DailyThe FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
InvestorPlace3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others t
